A retention decision for a university IP portfolio
A commercial viability assessment commissioned by a UK university enterprise office. Three patents from a single research group’s portfolio reframed as enabling IP for adoption by established commercial actors — not the basis for a new spinout.
The starting position
A UK university’s commercialisation office approached the engagement with a high-stakes triage question. Three interrelated patents from a single research group sat in the portfolio — technically credible, uncommitted commercially, and accruing annual prosecution costs. The TTO needed an evidence-based answer to a decision it had been deferring. Did these patents warrant retention and active commercial development, or should they be allowed to lapse?
The portfolio sat in a space familiar to any TTO managing IP from advanced engineering and applied science groups: the underlying science was well-established, but the practical adoption path remained unclear. Laboratory-scale feasibility was not the constraint. The constraints were specific to deployment, integration, and the commercial conditions under which industry would adopt.
The TTO did not need another technical review. The University’s own researchers knew science. What was missing was the commercial frame — a structured view of whether, where, and on what terms these patents could be commercialised.
What we did
The engagement was scoped and contracted as a paid commercial viability assessment. The work was anchored on a single decision: convert the portfolio’s assessed potential into an evidence-backed commercial recommendation, or recommend controlled wind-down.
The assessment deliberately resisted the trap of most IP reviews fall into — scoring patents against each other on abstract criteria. Instead, each patent was mapped to its natural point of adoption inside the eventual deployable system. Where it sits — at which architectural layer. What a partner would have to change to adopt it. What they would measure to confirm value. Which design-around routes would most plausibly influence claim strength.
That mapping translated into three connected outputs: a per-patent Competitiveness Matrix positioning each patent against its natural baseline; a per-patent Market Assessment naming primary adopter archetypes, buyer value drivers, acceptance criteria, and likely agreement form; and an Implementation Fit Matrix showing the specific change a partner would make to adopt each patent.
We ran the analysis against the field’s foundational and translational literature, so each patent could be assessed against documented commercialisation barriers rather than theoretical performance alone. The portfolio’s alignment with those documented barriers is what gave the retention case its evidential weight.
The commercial move
The most consequential decision in the assessment was the reframe from spinout to licensing.
The natural institutional reflex, faced with three credible patents, is to ask whether they could support a new spinout. That question has obvious appeal — spinouts are visible, fundable, celebrated — but in this case it was the wrong question.
The evidence pointed elsewhere. The three patents sat at different architectural layers of the eventual deployable system. Their combined commercial strength was as enabling IP for platforms being built by others, not as the technical core of a new standalone venture. None of the three, on its own profile, carried a new company. All of them carried a licence.
Two consequences follow from that reframe. The commercialisation work shifts from building a founder team and a funding round toward a defined, evidence-led engagement approach with prospective adopters. And the deal structure defaults away from blanket exclusivity, toward postures appropriate to the architectural layer at which each patent sits — broad adoption where breadth grows the addressable market; tighter scoping where architectural fit to a specific partner is what decides the deal.
For a university weighing prosecution spend against likelihood of return, the reframe matters. It is what separates a portfolio that accrues renewal costs indefinitely from one with a defined commercial form, defined adopter archetypes, and defined conditions under which effort should be narrowed.
What the engagement produced
- A retention recommendation — the portfolio justified continued prosecution and active commercialisation on a licensing basis, with a controlled narrowing rule if commercial traction did not materialise within a bounded period.
- A per-patent Competitiveness Matrix positioning each patent against its natural baseline, with differentiation strength and design-around risk quantified.
- A per-patent Market Assessment naming primary adopter archetypes, priority use cases, buyer value drivers, indicative acceptance criteria, procurement entry routes, and agreement form.
- An Implementation Fit Matrix translating each patent into the specific change a partner would make to adopt it and the evidence that would most plausibly trigger commercial terms.
- A licensing posture calibrated to the architectural layer at which each patent sits — designed to protect University value without granting exclusivity before technical fit is confirmed.
- A structural reasoning framework for engagement with the prospective adopter community, sufficient to guide University-led outreach while preserving confidentiality around specific counterparties.
Why it matters
Universities carry hundreds of patents through annual renewal cycles that nobody has time to re-evaluate. The institutional cost of that drift — in prosecution fees, in TTO bandwidth, in missed licensing windows — is rarely made visible, because nobody is paid to make the retention decision explicit. Most portfolio reviews either over-promise (every patent is a potential spinout) or under-promise (nothing here is commercial). Neither is honest, and neither produces a decision that can be acted on.
This engagement illustrates what an honest retention decision looks like when it is done with commercial rigour. The question was not “can these patents be sold” but “what is the commercial form this portfolio can credibly take, and what evidence would tell us whether that form works.” The answer was specific. Licensing, not spinout. Enabling IP, not foundational. A licensing posture calibrated to the architectural layer at which each patent sat.
That kind of retention work is easy to undervalue. It does not produce a headline event. It produces a decision a TTO can defend on evidence — to keep prosecuting, to narrow, or to let go. For a TTO managing a portfolio under pressure, which is worth more than another speculative spinout assessment.
A note on status
The engagement and its findings remain commercially confidential. This case study describes Hatch Oxford’s methodology at the level it can be discussed publicly. The client, the technology, the specific findings, and any counterparties are not identified.
